Expression and clinical significance of SLC19A3 in breast cancer and effects of Bufalin on the expression of SLC19A3: analysis based on the data-mining from bioinformatics
LI Dan1 YU Tao2,3 LI Jing1 ZHANG Fan1 ZENG Junfen1 PENG Yan1
1.Department of Pharmacy, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China;
2.Department of Oncology of Integrated Chinese and Western Medicine, Wuhan Central Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Hubei Province, Wuhan 430014, China;
3.Teaching and Research Office of Diagnostics of Chinese Medicine, College of Basic Medicine, Hubei University of Chinese Medicine, Hubei Province, Wuhan 430065, China
Abstract：Objective To analyze the expression and its clinical significance of SLC19A3 gene in breast cancer and to explore the effects of Bufalin on the expression of SLC19A3 in breast cancer cells. Methods The datasets about breast cancer and effects of Bufalin on breast cancer cell were retrieved from Oncomine and GEO database, and the datasets were deeply mined and analyzed with literature. SLC19A3 mRNA expression between normal group and breast cancer group as well as correlation with prognosis were analyzed. Meanwhile, the effect of Bufalin on the expression level of SLC19A3 gene in breast cancer cells was also analyzed. Results The expression of SLC19A3 gene in breast cancer tissues was significantly higher than that of breast normal tissues through mining and analyzing the 9 datasets about SLC19A3 gene in breast carcinoma from Oncomine database (P ＜ 0.05). Survival analysis showed that the disease-free survival of breast cancer patients with higher expression of SLC19A3 gene was significantly better than the patients with lower expression of SLC19A3, and the prognosis of patients with high expression of SLC19A3 gene was better (P ＜ 0.05). Finally, the mRNA expression of SLC19A3 gene was up-regulated by Bufalin in the datasets of GSE85871 through mining the GEO database (P ＜ 0.01). Conclusion SLC19A3 gene is under-expressed in breast cancer and its expression level is related to the prognosis of breast cancer, which may be a new target of effects of Bufalin on breast cancer cells.
李丹1 余涛2,3 李景1 张帆1 曾俊芬1 彭燕1. 基于生物信息学分析SLC19A3基因在乳腺癌中的表达意义及蟾毒灵的干预研究[J]. 中国医药导报, 2018, 15(17): 12-16.
LI Dan1 YU Tao2,3 LI Jing1 ZHANG Fan1 ZENG Junfen1 PENG Yan1. Expression and clinical significance of SLC19A3 in breast cancer and effects of Bufalin on the expression of SLC19A3: analysis based on the data-mining from bioinformatics. 中国医药导报, 2018, 15(17): 12-16.
[1] Nabokina SM，Reidling JC，Said HM. Differentiation-dependent up-regulation of intestinal thiamin uptake：cellular and molecular mechanisms [J]. J Biol Chem，2005，280（38）：32676-32682.
[2] Eudy JD，Spiegelstein O，Barber RC，et al. Identification and characterization of the human and mouse SLC19A3 gene：a novel member of the reduced folate family of micronutrient transporter genes [J]. Mol Genet Metab，2000， 71（4）：581-590.
[3] Zhao R，Goldman ID. Folate and thiamine transporters mediated by facilitative carriers （SLC19A1-3 and SLC46A1）and folate receptors [J]. Mol Aspects Med，2013，34（2/3）：373-385.
[4] Dutta B，Huang W，Molero M，et al. Cloning of the human thiamine transporter， a member of the folate transporter family [J]. J Biol Chem，1999，274（45）：31 925-31 929.
[5] Said HM，Balamurugan K，Subramanian VS，et al. Expression and functional contribution of hTHTR-2 in thiamin absorption in human intestine [J]. Am J Physiol Gastrointest Liver Physiol，2004，286（3）：491-498.
[6] Zera K，Sweet R，Zastre J. Role of HIF-1alpha in the hypoxia inducible expression of the thiamine transporter，SLC19A3 [J]. Gene，2016，595（2）：212-220.
[7] Sweet R，Paul A，Zastre J. Hypoxia induced upregulation and function of the thiamine transporter，SLC19A3 in a breast cancer cell line [J]. Cancer Biol Ther，2010，10（11）：1101-1111.
[8] Liu S，Monks NR，Hanes JW，et al. Sensitivity of breast cancer cell lines to recombinant thiaminase I [J]. Cancer Chemother Pharmacol，2010，66（1）：171-179.
[9] Ng EK，Leung CP，Shin VY，et al. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients [J]. PLoS One，2011，6（7）：e22233.
[10] Curtis C，Shah SP，Chin SF，et al. The genomic and transcriptomic architecture of 2，000 breast tumours reveals novel subgroups [J]. Nature，2012，486（7403）：346-352.
[11] Radvanyi L，Singh-Sandhu D，Gallichan S，et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer [J]. Proc Natl Acad Sci USA，2005，102（31）：11005-11010.
[12] Glück S，Ross JS，Royce M，et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capeci-tabine ± trastuzumab [J]. Breast Cancer Res Treat，2012， 132（3）：781-791.
[13] Cheuk IW，Shin VY，Siu MT，et al. Association of EP2 receptor and SLC19A3 in regulating breast cancer metastasis [J]. Am J Cancer Res，2015，5（11）：3389-3399.
[14] Ikehata M，Ueda K，Iwakawa S. Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines [J]. Biol Pharm Bull，2012，35（3）：301-307.
[15] Liu X，Lam EKY，Wang X，et al. Promoter hypermethylation mediates downregulation of thiamine receptor SLC19A3 in gastric cancer [J]. Tumour Biol，2009，30（5/6）：242-248.
[16] 苏永华.华蟾素注射液治疗肝癌的疗效、有效成份及作用机制研究[D].上海：第二军医大学，2003.
[17] 王琳，李泉旺，周天，等.华蟾素对大鼠膀胱癌组织VEGF及微血管密度的影响[J].环球中医药，2018，11（2）：182-185.
[18] 闫顺朝，焦昕，李凯，等.蟾毒灵与紫杉醇协同抑制乳腺癌细胞增殖的机制[J].现代肿瘤医学，2016，24（20）：3173-3176.
[19] 柯红，崔洁，金锦莲，等.华蟾素胶囊联合CAF方案治疗中晚期乳腺癌的临床效果分析[J].世界中医药，2017，12（10）：2358-2361.
[20] 陈建英，胡先全，黄三雄，等.华蟾素胶囊联合GP方案对晚期非小细胞肺癌患者免疫功能的影响[J].中国现代医生，2016，54（14）：12-15.
[21] 闫顺朝，焦昕，李凯，等.蟾毒灵与顺铂协同抑制乳腺癌MCF-7细胞增殖的机制探讨[J].临床肿瘤学杂志，2016， 21（12）：1057-1062.
[22] 田怀平，杨宇，杨萍，等.华蟾素经肝动脉栓塞灌注给药治疗中晚期原发性肝癌的系统评价[J].环球中医药，2016，9（10）：1175-1179.
[23] 闫顺朝，曲秀娟，邹华伟，等.蟾毒灵通过下调c-Flip和XIAP增强TRAIL诱导的乳腺癌MDA-MB-231细胞凋亡[J].现代肿瘤医学，2014，22（8）：1748-1752.
2018, Vol. 15 
京公网安备 11010502046598号